Clinical trial • Oncology
Clinical trial in Glioblastoma multiforme|Glioblastoma
Clinical trial for Glioblastoma multiforme|Glioblastoma. 27 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Glioblastoma multiforme|Glioblastoma
- Drug Modality
- Gene therapy|Cell therapy
Key dates
- Initial CTIS Submission Date
- 26-01-2024
- First CTIS Authorization Date
- 28-02-2024
Trial design
Clinical trial across 3 sites in Italy.
- Target Sample Size
- 27
Eligibility
Recruits 27 Vulnerable population selected; no details on consent or assent provided in the available CTIS data..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent provided in the available CTIS data.
Recruitment
- Planned Sample Size
- 27
- Recruitment Window Months
- 86
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 27
Italy
- Earliest CTIS Part Ii Submission Date
- 05-02-2024
- Latest Decision Or Authorization Date
- 28-02-2024
- Processing Time Days
- 23
- Number Of Sites
- 3
- Number Of Participants
- 27
Sites
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo
- Principal Investigator Name
- Alessandro Olivi
- Principal Investigator Email
- alessandro.olivi@policlinicogemelli.it
- Contact Person Name
- Alessandro Olivi
- Contact Person Email
- alessandro.olivi@policlinicogemelli.it
- Site Name
- Ospedale San Raffaele S.r.l.
- Department Name
- U.O. Ematologia e Trapianto Midollo Osseo
- Principal Investigator Name
- Fabio Ciceri
- Principal Investigator Email
- ciceri.clinicaltrials@hsr.it
- Contact Person Name
- Fabio Ciceri
- Contact Person Email
- ciceri.clinicaltrials@hsr.it
- Site Name
- IRCCS Foundation Istituto Neurologico Carlo Besta
- Department Name
- U.O. Neurologia VIII - Neuro-oncologia Molecolare
- Principal Investigator Name
- Marica Eoli
- Principal Investigator Email
- marica.eoli@istituto-besta.it
- Contact Person Name
- Marica Eoli
- Contact Person Email
- marica.eoli@istituto-besta.it
Sponsor
Primary sponsor
- Full Name
- Genenta Science S.p.A.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Italy
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)